How research excellence on diabetes can stimulate growth in Sweden
| Reference number | |
| Coordinator | Lunds universitet - Lunds Universitets Diabetes Centrum |
| Funding from Vinnova | SEK 500 000 |
| Project duration | August 2012 - September 2013 |
| Status | Completed |
Important results from the project
Prioritized areas that are key to create better conditions for translating basic research results to patient benefit have been identified, the prioritized areas have been anchored in relevant stakeholder groups, and concrete initiatives have been recommended. The initiatives will result in more viable innovation projects, which will create growth in new and existing companies. Some initiatives have already been implemented; others will be included in a SIO-application. Some initiatives may start immediately; others will require more long-term structural changes.
Expected long term effects
Our agenda has created a broad consensus around bottlenecks that contribute to slow translation of basic research to patient benefit, and around a concrete action plan, which will create new innovation projects, new jobs, a more competitive Swedish life science sector, and thereby facilitate the development of new and innovative solutions for the grand challenge that diabetes presents.
Approach and implementation
In order to secure a broad consensus between stakeholders, we have engaged in dialogue with a large part of the ecosystem, which has given feedback on our proposed initiatives. Following interaction with other life science agendas, we have merged with SILS, with the aim to create a SIO within the life sciences. This SIO will have diabetes as a pilot area. This means that additional stakeholders are reached, including decision makers in all the large health care regions. This will increase our chances of making our vision for the life science sector in Sweden come true.